Influenza vaccination in failing hearts

Affiliations

¹ Cardiocenter of the Third Faculty of Medicine Charles University and the University Hospital Kralovske Vinohrady, Prague 100 34, Czech Republic. Electronic address: zuzana.motovska@lf3.cuni.cz.
² Department of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls Universtität Tübingen, Tübingen, Germany.

Free article

Comment

Zuzana Motovska et al. Lancet Glob Health. 2022 Dec.

Free article

. 2022 Dec;10(12):e1703-e1704.

doi: 10.1016/S2214-109X(22)00471-5.

¹ Cardiocenter of the Third Faculty of Medicine Charles University and the University Hospital Kralovske Vinohrady, Prague 100 34, Czech Republic. Electronic address: zuzana.motovska@lf3.cuni.cz.
² Department of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls Universtität Tübingen, Tübingen, Germany.

No abstract available

Conflict of interest statement

We declare no competing interests.

Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial.
Loeb M, Roy A, Dokainish H, Dans A, Palileo-Villanueva LM, Karaye K, Zhu J, Liang Y, Goma F, Damasceno A, Alhabib KF, Yonga G, Mondo C, Almahmeed W, Al Mulla A, Thanabalan V, Rao-Melacini P, Grinvalds A, McCready T, Bangdiwala SI, Yusuf S; Influenza Vaccine to Prevent Adverse Vascular Events investigators. Loeb M, et al. Lancet Glob Health. 2022 Dec;10(12):e1835-e1844. doi: 10.1016/S2214-109X(22)00432-6. Lancet Glob Health. 2022. PMID: 36400089 Clinical Trial.